Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome
Digestive and Liver Disease, Volume 47, No. 2, Year 2015
Notification
URL copied to clipboard!
Description
Background: Triple therapy with telaprevir/boceprevir + pegylated-interferon + ribavirin can achieve excellent antiviral efficacy, but it can be burdened with resistance development at failure. Aims: To evaluate kinetics of hepatitis C virus (HCV) RNA decay and early resistance development, in order to promptly identify patients at highest risk of failure to first generation protease inhibitors. Methods: HCV-RNA was prospectively quantified in 158 patients receiving pegylated-interferon + ribavirin + telaprevir (N= 114) or + boceprevir (N= 44), at early time-points and during per protocol follow-up. Drug resistance was contextually evaluated by population sequencing. Results: HCV-RNA at week-2 was significantly higher in patients experiencing virological failure to triple-therapy than in patients with sustained viral response (2.3 [1.9-2.8] versus 1.2 [0.3-1.7] log IU/mL, p< 0.001). A 100. IU/mL cut-off value for week-2 HCV-RNA had the highest sensitivity (86%) in predicting virological success. Indeed, 23/23 (100%) patients with undetectable HCV-RNA reached success, versus 26/34 (76.5%) patients with HCV-RNA < 100. IU/mL, and only 11/31 (35.5%) with HCV-RNA > 100 IU/mL (p< 0.001). Furthermore, differently from failing patients, none of the patient with undetectable HCV-RNA at week-2 had baseline/early resistance. Conclusions: With triple therapy based on first generation protease inhibitors, suboptimal HCV-RNA decay at week-2 combined with early detection of resistance can help identifying patients with higher risk of virological failure, thus requiring a closer monitoring during therapy. © 2014 Editrice Gastroenterologica Italiana S.r.l.
Authors & Co-Authors
Cento, Valeria
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Di Paolo, Daniele
Italy, Rome
Policlinico Tor Vergata
Di Carlo, D.
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Micheli, Valeria
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Aragri, Marianna
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Antonucci, Francescopaolo
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Di Maio, Velia Chiara
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Mancon, Alessandro
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Lenci, Ilaria
Italy, Rome
Policlinico Tor Vergata
Taliani, Gloria L.
Italy, Rome
Sapienza Università Di Roma
Di Biagio, Antonio
Italy, Genoa
Irccs San Martino Polyclinic Hospital
Nicolini, Laura Ambra
Italy, Genoa
Irccs San Martino Polyclinic Hospital
Siciliano, Massimo
Italy, Rome
Università Cattolica Del Sacro Cuore, Campus Di Roma
Landonio, Simona
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Pellicelli, A. M.
Italy, Rome
Azienda Ospedaliera San Camillo Forlanini
Magni, Carlo Federico
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Babudieri, Sergio
Italy, Sassari
Università Degli Studi Di Sassari
Andreoni, Massimo G.
Italy, Rome
Policlinico Tor Vergata
Parruti, Giustino
Italy, Pescara
Pescara General Hospital
Rizzardini, Giuliano
Italy, Milan
Ospedale Luigi Sacco - Polo Universitario
Angelico, Mario
Italy, Rome
Policlinico Tor Vergata
Perno, Carlo Federico
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Ceccherini-Silberstein, Francesca
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Statistics
Citations: 5
Authors: 23
Affiliations: 10
Identifiers
Doi:
10.1016/j.dld.2014.11.010
ISSN:
15908658
Research Areas
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study
Cohort Study